Akebia Therapeutics (NasdaqCM:AKBA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAshleigh Acker - Biotechnology Equity Research AssociateErik Ostrowski - CFO and Chief Business OfficerJohn Butler - President, CEO, and DirectorMercedes Carrasco - Senior Director of Investor and Corporate CommunicationsNicholas Grund - Chief Commercial OfficerSteven Burke - Chief Medical OfficerConference Call ParticipantsJulian Harrison - Managing Director and Biotechnology AnalystMichael Cherny - ...

Akebia Therapeutics (NasdaqCM:AKBA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsErik Ostrowski - CFO and Chief Business OfficerJohn Butler - President, CEO, and DirectorMercedes Carrasco - Senior Director of Investor and Corporate CommunicationsNicholas Grund - Chief Commercial OfficerSteven K. Burke - Senior Vice President, Chief Research and Development OfficerConference Call ParticipantsJulian Harrison - Managing Director and Biotechnology AnalystManagi Nassar - Senior Equity ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 245 First Street, Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (6 ...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare ...

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the best growth stocks to buy for the next 20 years. On February 6, Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia to $4 from $6 and kept an Overweight rating. This adjustment was made as part of a broader review of commercial-stage companies, with the firm updating estimates and price targets following several year-end preliminary reports and ahead of official Q4 2025 results. In Q3, Akebia Therapeutics Inc. (NASDAQ:AKBA) ...

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and yo ...

Core Viewpoint - The presentation is part of the Guggenheim Emerging Outlook: Biotech Summit, focusing on the latest developments in the biotech sector, particularly featuring Akebia Therapeutics and its leadership team [1]. Company Overview - Akebia Therapeutics is represented by its CEO John Butler, CMO Steve Burke, and CFO/CBO Erik Ostrowski at the conference, indicating a strong leadership presence [2]. - The company aims to provide an overview of its current status and developments, highlighting the evolution of its story over the past few years [3].

Akebia Therapeutics Conference Summary Company Overview - **Company**: Akebia Therapeutics (NasdaqCM:AKBA) - **Focus**: Improving the lives of individuals affected by kidney disease - **Commercial Products**: - Auryxia: A phosphate binder nearing the end of its life cycle - VAFSEO: A HIF-PHI for treating anemia in chronic kidney disease patients on dialysis, launched about a year ago [4][5] Key Points on VAFSEO - **Initial Uptake**: Strong initial uptake observed post-launch, but faced challenges due to the unique nature of the dialysis market [7][8] - **Market Dynamics**: Dialysis providers control the prescription process, affecting product availability [8] - **Discontinuation Rates**: Higher than expected due to initial hemoglobin dips in patients; efforts are being made to improve patient retention [10][12] - **Dosing Strategy**: Transitioning to a three times weekly (TIW) dosing regimen has shown promising results in reducing discontinuation rates [12][13] - **Patient Access**: By the end of 2025, access to approximately 275,000 patients was achieved [13] - **Long-term Growth**: Data supporting VAFSEO's potential to become the standard of care for anemia in dialysis patients is anticipated [14][24] Clinical Trials and Studies - **VOCAL and VOICE Trials**: - VOCAL: A study comparing VAFSEO to Mircera, expected to show excellent hemoglobin control [20][29] - VOICE: A randomized comparison against Epogen, with results expected early in 2027 [29][31] - **Economic Perspective**: Demonstrating reduced hospitalization costs could enhance the economic proposition for dialysis organizations [31] Pipeline Developments - **Rare Kidney Disease Pipeline**: - Praliciguat: Phase II study initiated for FSGS, targeting rapid progression to end-stage kidney disease [5][40] - AKB-097: A tissue-targeted complement inhibitor, with a basket study planned for IgAN, C3G, and lupus nephritis [40][58] - **Mechanistic Rationale**: Praliciguat stimulates soluble guanylate cyclase, beneficial for podocytes and anti-inflammatory [42][44] - **Patient Focus**: Targeting primary FSGS and genetic mutation-related FSGS while excluding secondary causes [56] Financial Position - **Cash Reserves**: $166 million as of Q3, with at least two years of cash runway [69] Upcoming Catalysts - **Key Events**: - Continued monitoring of VAFSEO's market performance - Progress on Praliciguat and AKB-097 studies - Results from VOCAL and VOICE trials expected within the next 12 months [70][72] Conclusion - **Outlook**: The next 12 months are anticipated to be critical for Akebia, with significant clinical readouts and potential market shifts for VAFSEO and pipeline products [72]

Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [3]. Event Participation - Members of Akebia's executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12 at 9:30 AM EST [1]. - The Emerging Outlook: Biotech Summit will be held from February 11-12 in New York City [2]. Webcast Information - A webcast of the presentation will be available in the "Investors" section of Akebia's website following the conference [2].

Company Overview - Akebia Therapeutics, Inc. (AKBA) primarily generates revenue through the commercialization of Vafseo, an oral therapy approved for treating anemia due to chronic kidney disease (CKD) in adults [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience as a lab technician in drug discovery, providing a strong foundation in the challenges of drug development [1] - The analyst has been active in the investment space for five years, focusing on biotechnology companies that innovate through unique mechanisms, first-in-class therapies, or platform technologies [1] Investment Focus - The analyst aims to identify promising biotechnology companies and evaluates the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals and valuation [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector, which can yield significant returns through breakthrough science [1]